Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169371 · ClinicalTrials.gov registry record · Phase 4
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
A Phase 4 study of Breast Cancer, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT06169371: Recruiting Phase 4 study of Breast Cancer, sponsored by University of Illinois at Chicago.
NCT06169371 is a Phase 4 study of Breast Cancer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06169371, a Phase 4 study of Breast Cancer, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Primary Outcome
Number of subjects that continue to receive Abemaciclib 150mg BID for 84 days
Conditions Studied
Interventions
- DRUG Abemaciclib
Study Locations (3)
Illinois
- University of Illinois - Chicago
Iowa
- Iowa Holden Comprehensive Cancer Center - Iowa City
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2030-11 |
| Phase | Phase 4 |
What NCT06169371 shows while recruiting
NCT06169371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.
NCT06169371 reports a single indexed study location in Illinois, Iowa, Ohio.
Frequently Asked Questions
What is clinical trial NCT06169371 about?
NCT06169371 is a clinical study titled "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)". This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of...
What is the current status of trial NCT06169371?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-12-28. Estimated completion is 2030-11.
What conditions does trial NCT06169371 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06169371?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT06169371?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06169371 being conducted?
This trial has 3 study locations across Illinois, Iowa, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06169371's enrollment target sits among peer trials
50 789th of 1224 higher than 410 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI